Chapter 15: Monitoring tuberculosis program performance

Figures & data

Figure 1. Actual incidence of TB in Canada.

Actual incidence: Reported cases from the Notifiable diseases on-line (PHAC)²⁰ 1924 to 2019 in Canada

1997 target: 5% annual reduction in cases²¹

2006 target: Reach a target incidence of 3.6 by 2015. A linear relationship was plotted and extended beyond the 2015 goal.²²

2015 target: Reduce new incident cases by 90% in 2035 as compared to 2015.⁴ Note that these case numbers are for Canada overall and differ for select populations within Canada.

Table 1. Indicators and related targets.

Elimination Goals
	Key Indicator	Definition	Target
1.0	Total annual incidence (crude) rate of tuberculosis (TB), all forms	The total number of people notified with TB in the jurisdiction, expressed as a rate per 100,000 population	Pre-elimination target set at an active case rate of 1/100,000 or, as above, 10/1,000,000 population by 2035
Objectives for examination of immigrants and refugees
2.0	Of people whose immigration medical examination (IME) indicated follow-up, the proportion (%) of individuals who are evaluated by a TB clinician	The total number of appointments attended among persons whose IME led to a referral to public health for medical surveillance of TB	≥90%
Objectives for case management and treatment
3.0	Of all people with new, relapse, or retreatment TB, proportion (%) with known human immunodeficiency virus (HIV) status	The number of people with annual incident TB whose HIV status is known at the start date of treatment	>95%
3.1	Of all people with smear-positive, pulmonary TB, proportion (%) started treatment within 72 hours of positive nucleic acid amplification test (NAAT)	The number of people with annual incident, smear-positive pulmonary TB cases who are started on anti-TB drugs within 72 hours of a positive NAAT result	≥95%
3.2	Of all people with smear-positive, pulmonary TB, proportion (%) started on 4 or more anti-TB drugs to which they are likely to be susceptible^a	The number of people with annual incident smear-positive, rifampin-susceptible (by NAAT), pulmonary TB who start 4 anti-TB drugs in the absence of any risk factors for resistance, or hepatoxicity	≥95%
3.3	Of all people with culture positive, pulmonary TB, proportion (%) with sputum submitted for acid fast bacillus (AFB) smear/culture, and a chest radiograph (CXR) at the end of the initial phase of treatment	The number of people with annual incident culture-positive, pulmonary TB who have sputum submitted for AFB smear and culture, and have a CXR performed within 2 weeks of the end of the initial phase of treatment	≥95%
3.4	Of all patients who started treatment for active disease in the preceding 12 months, the proportion (%) who achieved treatment success (cure or completed)^b	The proportion of patients notified in the preceding 12 months who were cured or completed treatment	≥90%
3.5	Does the TB program have dedicated social worker support to provide patient-centered care?	TB disease is considered a biologic expression of social inequity, thereby requiring solutions that consider social and structural factors* *See text below for more details.	Yes
Objectives for contact management
4.0	Of all close contacts of people with smear-positive, pulmonary TB, proportion (%) whose initial contact encounter is within 3 working days of having been listed as a contact	The number of close contacts of people with smear-positive, pulmonary TB, whose initial contact encounter occurred within 3 working days of having been named as a contact	≥95%
4.1	Of all close contacts of people with smear-positive, pulmonary TB, proportion (%) completely assessed	The number of close contacts (household and non-household) of people with smear-positive, pulmonary cases, whose assessments are completed	≥95%
4.2	Of all close contacts of people with smear-positive, pulmonary TB with a diagnosis of latent TB infection (LTBI), proportion (%) who began treatment	The number of close contacts of people with smear-positive, pulmonary TB with a diagnosis of LTBI who initiate preventive therapy within 12 months of source diagnosis	≥90%
4.3	Of all close contacts of people with smear-positive, pulmonary TB with a diagnosis of LTBI, proportion (%) completed treatment	The number of close contacts of people with smear-positive, pulmonary TB who complete treatment with TB preventive therapy after initiating	≥90%

a Exclusions listed in definition, and supplement.

b Outcomes are available/known only for cases who were diagnosed/initiated treatment in the year prior to reporting of all other indicators.

Table

Goal of Elimination
Indicator, Target and Rationale	Notes
1.0 Crude incidence rate of TB: all forms Target: Report incidence, and rate of decline. Rationale: This is the hard target of pre-elimination and elimination. This measurement establishes the ultimate standard by which the program is performing. Incidence should be monitored and reported annually to inform effective mid-course changes on the path to elimination. ^56 ^, ^57 Canada is responsible for reporting national and subnational data to the global community; therefore, these data should be accessible and reportable. ^58	Program leads should establish a rate of decline that is adequate to achieve elimination targets.
Precedence
Recommended internationally by: WHO- Compendium of Indicators for Monitoring and Evaluation of National Tuberculosis Control Programs; ^56 CDC - National Tuberculosis Program Objectives and Performance Targets for 2025; ^59 Australia - The Strategic Plan for Control of Tuberculosis in Australia 2011-2015, and National Tuberculosis Performance Indicators, Australia 2013-2014; ^5, ^60 Public Health England - Public Health England Tuberculosis Strategy Monitoring Indicators 2015-2020 (three-year average) ^7 Alaska – Alaska Department of Health and Social Services TB Manual ^1 ; Minnesota – Tuberculosis (TB) Prevention and Control Program; ^62 and California – CID TB Performance Trends for US, California Objectives. ^63	Recommended for Canada by: Pan-Canadian Public Health Network - Guidance for Tuberculosis Prevention and Control Programs in Canada; ^15 FNIHB - Health Canada Strategy against Tuberculosis for First Nations on-Reserve and Monitoring and Performance Framework; ^13, ^14 Inuit Tuberculosis Elimination Framework; ^16 Heffernan & Long - Would program performance indicators and a nationally coordinated response accelerate tuberculosis elimination in Canada?; ^64 and NCCID - Toward TB Elimination: Shared Priorities for TB Program Performance Measurement in Canada, a Proposal for Discussion. ^17

Table

Objectives for examination of immigrants and refugees
Indicator, Target and Rationale	Notes
2.0 Proportion of individuals referred for immigration medical surveillance who are evaluated by physician Target: ≥90% Rationale: Foreign-born persons contribute the absolute highest number of total cases identified in Canada (now >70% nationally), creating pressure on the pace of decline that can be achieved domestically. ^26 ^, ^33 A systematic and meta-review of TB incidence among migrants deemed ‘high-risk’ in pre-migration screening reported an elevated incidence of active disease in this group. The pooled cumulative incidence of TB post-migration in the study population from 22 cohorts was 2,794 per 100,000 persons (95% CI 2179-3409; I^2 = 99%). The pooled cumulative incidence of TB at the first follow-up visit from ten cohorts was 3,284 per 100,000 persons (95% CI 2173-4395; I^2 = 99%). The pooled TB incidence from 15 cohorts was 1,249 per 100,000 person-years of follow-up (95% CI 924-1574; I^2 = 98%). ^65 There is recent debate about whether the phenotypic expression of disease in newcomers poses a significant public health risk, suggesting that the risk of in-country transmission is limited compared to the risk of transmission by people who develop reactivation pulmonary disease from undetected LTBI on arrival. ^28 ^, ^66 As a result, this indicator alone is insufficient for long-term reduction of TB in foreign-born persons. Although referral of foreign-born persons to public health for medical surveillance is understood to be minimal ^67 in contributing to elimination, targeted screening for LTBI among immigrants and refugees arriving in Canada has not yet reached its potential.	Despite the limitations, this performance indicator is a measurable aspect of TB prevention and care services and helps generate evidence in support of value (ROI).
Precedence
Recommended internationally by: CDC - National Tuberculosis Program Objectives and Performance Targets for 2025; ^59 California – CID TB Performance Trends for US, California Objectives ^63 ; and Public Health England - Public Health England Tuberculosis Strategy Monitoring Indicators 2015-2020. ^61	Recommended for Canada by: Pan-Canadian Public Health Network -Guidance for Tuberculosis Prevention and Control Programs in Canada; ^15 Heffernan & Long - Would program performance indicators and a nationally coordinated response accelerate tuberculosis elimination in Canada?. ^64 Chapter 15 of the sixth Edition of the Canadian Tuberculosis Standards, Immigration and Tuberculosis Control in Canada records an evaluation of compliance on this indicator done at the national level (average performance reported to be about 50% at the time). ^68

Table

Objectives for case management and treatment
Indicator, Target and Rationale	Notes
3.0 Proportion of all new, relapse, or re-treatment TB cases whose HIV status is known Target: ≥95% Rationale: A diagnosis of HIV, independent of TB, has individual and public health implications ^69 and, in the event of co-infection, has implications for treatment. In Alberta, where >90% of TB patients are HIV tested (attributable to an opt-out strategy), nearly 50% of HIV infections are discovered at the time of a TB diagnosis. ^70 A recent systematic review and meta-analysis of the adoption of indicator condition-guided HIV testing in Western nations showed that there has been scarce reporting of HIV testing of TB patients in Canada (4/28 articles), with variability in achievement ranging from 53.6 to 90.6% known HIV status during TB treatment. This indicates both a greater need for reporting as well as implementation of strategies to improve adherence to recommendations at the program level. ^71	The target is to offer an HIV test to all incident TB cases if HIV status is unknown at the time of diagnosis, 100% of the time; it is understood that the rate of acceptance will be lower.
Precedence
Recommended internationally by: WHO - Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs; ^56 Horsburgh et al. – Practice Guidelines for the Treatment of Tuberculosis; ^34 WHO – End TB Strategy ^4 ; WHO/UNAIDS – Guide to Monitoring and Evaluation for Collaborative TB/HIV activities; ^72 Australia - The Strategic Plan for Control of Tuberculosis in Australia 2011-2015, and National Tuberculosis Performance Indicators, Australia 2013-2014; ^5 ^, ^60 Public Health England - Public Health England Tuberculosis Strategy Monitoring Indicators 2015-2020 (three-year average); ^7 Alaska – Alaska Department of Health and Social Services TB Manual; ^61 and, California – CID TB Performance Trends for US, California Objectives. ^63	Recommended for Canada by: Canadian Tuberculosis Directors of Canada and the Department of National Health and Welfare in consultation with P/T epidemiologists - Guidelines for the identification, investigation and treatment of individuals with concomitant tuberculosis and HIV infection; ^73 Canadian Tuberculosis Committee, Health Canada - Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts; ^74 Pan-Canadian Public Health Network - Guidance for Tuberculosis Prevention and Control Programs in Canada; ^15 and Haworth-Brockman & Keynan - Strengthening tuberculosis surveillance in Canada. ^75
Indicator, Target and Rationale	Notes
3.1 Proportion of all smear-positive, pulmonary cases who start treatment within 72 hours of positive NAAT Target: ≥95% Rationale: Timely treatment initiation provides an individual benefit by limiting increased risk of complications associated with delay as well as a public health benefit, by rapidly reducing infectivity. ^76 A prospective cohort study in the United States found an increased risk of transmission to close contacts (outcome = TST positivity) of US-born patients who experienced a delay in treatment initiation ≥90 days (40%) vs those who had a shorter delay in treatment initiation (24%) (aOR 2.34; p = 0.03), and increasing to (aOR 3.29; p = 0.01) among close contacts of US-born patients sputum smear-positive for AFB and whose treatment initiation was delayed. ^77 Accordingly, rapid initiation of anti-TB drugs for pulmonary cases is a priority, and program performance should be leading in these patients.	The indicator and related target here is to initiate treatment rapidly (within 3 days), ≥95% of the time. This choice was based on the proficiency turnaround time expectation for labs to perform, and report results of the test within 24 hours of submission. Two additional days are proposed to allow for the possibility that notification of a positive NAAT may occur at the beginning of a long weekend.

Precedence
Recommended internationally by: CDC - National Tuberculosis Program Objectives and Performance Targets for 2025; ^59 Alaska – Alaska Department of Health and Social Services TB Manual^61; and California – CID TB Performance Trends for US, California Objectives. ^63	Recommended for Canada by: Pan-Canadian Public Health Network - Guidance for Tuberculosis Prevention and Control Programs in Canada. ^15
Indicator, Target and Rationale
3.2 Proportion of smear-positive pulmonary cases who start four or more anti-TB drugs Target: ≥95% Rationale: Rapid initiation of anti-TB drugs, especially for smear-positive pulmonary cases, is critical to reduce infectivity and interrupt transmission. ^76 ^, ^78 Given this reality, and in light of the delays associated with obtaining drug susceptibility test results, the greater individual and public health benefits derive from initiating empiric treatment among those infectious cases without risk factors for resistance, suspicion of hepatoxicity or gout. Of note, in Canada, drug resistance is a relatively infrequent phenomenon, but there is variability in the regional epidemiology of drug-resistant forms of TB that could contribute to more frequent exceptions to the numerator that some programs can anticipate. ^79
Precedence
Recommended internationally by: CDC -National Tuberculosis Program Objectives and Performance Targets for 2025;^59 and Public Health England - Public Health England Tuberculosis Strategy Monitoring Indicators 2015-2020. ^7	Recommended for Canada by: Pan-Canadian Public Health Network - Guidance for Tuberculosis Prevention and Control Programs in Canada; ^15 FNIHB/Health Canada - Strategy against Tuberculosis for First Nations on-Reserve, and related Monitoring and Performance Framework; ^13, ^14 NCCID - Toward TB Elimination: Shared Priorities for TB Program Performance Measurement in Canada, a Proposal for Discussion; ^17 and Heffernan & Long - Would program performance indicators and a nationally coordinated response accelerate tuberculosis elimination in Canada? ^64
Indicator, Target and Rationale
3.3 Proportion of all culture-positive pulmonary cases who have sputum submitted for AFB smear/culture, and a CXR at the end of the initial phase of treatment Target: ≥95% Rationale: Sputum culture-conversion at the end of the initial phase is understood to be a good predictor of eventual cure; more significantly, there are implications for treatment. ^56 Sustained culture positivity, or having unclosed cavitation on CXR at the end of the initial phase of treatment, may be suggestive of treatment failure/relapse and induced drug resistance. ^80 A recent systematic review and meta-analysis of sputum conversion during effective treatment found 12, and 41% of persons with smear-positive disease, remained solid and liquid culture-positive, respectively, at the end of the initial phase of treatment but sub-group analyses by important covariates known to be independently associated with sputum conversion, such as HIV status, and cavitation, were limited. ^81 Monitoring adherence to best clinical practice provides useful information to the program relating to efforts that ostensibly improve treatment outcomes by reducing risk of relapse.

Table

Precedence
Recommended internationally by: WHO – Compendium of Indicators for Monitoring and Evaluation of National Tuberculosis Control Programs; ^56 California – CID TB Performance Trends for US, California Objectives; ^63 and CDC - National Tuberculosis Program Objectives and Performance Targets for 2025. ^59	Recommended for Canada by: Pan-Canadian Public Health Network - Guidance for Tuberculosis Prevention and Control Programs in Canada; ^15 and FNIHB/Health Canada - Strategy against Tuberculosis for First Nations on-Reserve, and related Monitoring and Performance Framework. ^13 ^, ^14
Indicator, Target and Rationale
3.4 Treatment success (cure or completed) within 12 months of starting treatment Target: ≥90% of cases Rationale: Treatment success (cure or completed) is essential to eliminating TB by preventing transmission, disease severity and death. Incomplete treatment or loss to follow-up can lead to drug resistance and transmission to others. A 1991 World Health Assembly resolution established a global target for treatment success to be 85%, but in low-HIV-prevalence settings with universal health coverage, a higher rate of achievement should be possible. ^82
Precedence
Recommended internationally by: WHO- Compendium of Indicators for Monitoring and Evaluation of National Tuberculosis Control Programs; ^56 CDC - National Tuberculosis Program Objectives and Performance Targets for 2025; ^59 Australia - The Strategic Plan for Control of Tuberculosis in Australia 2011-2015, and National Tuberculosis Performance Indicators, Australia 2013-2014; ^5, ^60 WHO – End TB Strategy ^4 ; Alaska – Alaska Department of Health and Social Services TB Manual; ^61 Minnesota – Tuberculosis (TB) Prevention and Control Program ^62 ; and California – CID TB Performance Trends for US, California Objectives. ^63	Recommended for Canada by: Pan-Canadian Public Health Network - Guidance for Tuberculosis Prevention and Control Programs in Canada; ^15 FNIHB/Health Canada - Health Canada Strategy against Tuberculosis for First Nations on-Reserve and Monitoring and Performance Framework; ^13, ^14 ITK - Inuit Tuberculosis Elimination Framework^16 ; and Heffernan & Long - Would program performance indicators and a nationally coordinated response accelerate tuberculosis elimination in Canada? ^64
Indicator, Target and Rationale
3.5 Does the TB program have dedicated social worker support? Target: Yes Rationale: This chapter recommends that TB programs have dedicated support of a social worker, and that their associated workflow be evaluated. Some examples of possible measurements of the social worker’s performance include: the proportion of patients who are connected to a primary care provider by the end of TB care; the proportion of patients experiencing homelessness, or are underhoused, who are adequately housed through their efforts; monitoring of patients who report crowded housing. The objective psycho-social needs of clients and patients may vary by jurisdiction, and should be clearly defined by the program manager/lead.
Precedence
Recommended by: A specific program performance indicator about whether TB programs have dedicated social worker support could not be located. Recommendations, however, to meet the psycho-social needs of patients and clients who suffer the effects of TB infection and disease are common, but practical guidance about how to achieve this remains limited. ^83 As a result, this indicator is included as a means to generate information about the practical steps programs take to address the impacts of structural, and social determinants of health in the lives of clients/patients served.

Table

Objectives for contact management
Indicator, Target and Rationale	Notes
4 Proportion of close contacts of persons with smear-positive pulmonary disease whose initial contact encounter occurs within 3 working days. Target: ≥95% Rationale: TB programs in Canada generally rely on a stone-in-pond method for unmasking evidence of transmission among contacts of persons with pulmonary TB. ^84 This method is considered favorable when the relative risk of transmission to contacts is higher than the risk of infection in the general public. ^84 ^, ^85 A public health benefit of timely contact investigations is limiting transmission into broader circles of contact. ^86 The rapid identification and initial encounter of close contacts of infectious source cases provides a mechanism for prioritization. A modification to stone-in-pond is the rapid assessment (prioritization) of vulnerable contacts (young children, and persons with immunocompromising conditions, notably HIV) who have been shown to be at risk of very rapid progression to disease. ^87 ^, ^88	Three days is considered timely and reasonable, but also somewhat arbitrary. ^86 The purpose is to monitor with the ambition to meet and exceed the target, redirecting efforts if underperforming.
Precedence
Recommended internationally by: CDC - Guidelines for the investigation of contacts of patients with infectious tuberculosis: Recommendations from the National Tuberculosis Controllers Association and the CDC. ^86	Recommended for Canada by: Chapter 12 of the seventh Edition of the Canadian Tuberculosis Standards, Contact follow-up and outbreak management in tuberculosis control. ^89
Indicator, Target and Rationale
4.1 Proportion of close contacts of persons with smear-positive pulmonary disease who are completely assessed Target: ≥95% Rationale: Prevention of reactivation TB is equally important to appropriate case management, especially of infectious cases, in its contribution to pre-elimination and elimination goals.
Precedence
Recommended internationally by: WHO - End TB Strategy ^4 ; CDC - National Tuberculosis Program Objectives and Performance Targets for 2025; ^59 and Public Health England - Public Health England Tuberculosis Strategy Monitoring Indicators 2015-2020 (in development). ^7	Recommended for Canada by: FNIHB/Health Canada - Strategy against Tuberculosis for First Nations on-Reserve, and related Monitoring and Performance Framework; ^12, ^13 and Heffernan & Long - Would program performance indicators and a nationally coordinated response accelerate tuberculosis elimination in Canada? ^64
Indicator, Target and Rationale	Notes
4.2 Proportion of close contacts of persons with smear-positive pulmonary disease eligible for TPT, who initiate treatment Target: ≥90% Rationale: LTBI is the seedbed of future cases but treatment of LTBI, in the absence of a risk of reinfection, is considered to be fully protective against reactivation TB. ^90–95 As a result, pairing the prevention of reactivation with excellent infectious source case management work as hand-in-glove strategies to reduce future incidence of TB. ^49 ^, ^90	Targets are ambitious, but performance here and with respect to completion are likely to benefit from the current wealth of research aimed at reducing treatment duration and pill burden while maintaining efficacy and safety, as the expanded use of 4 R compared to the long-standing 9INH has shown. ^96 ^, ^97

Table

Precedence
Recommended internationally by: WHO- End TB Strategy; ^4 CDC - National Tuberculosis Program Objectives and Performance Targets for 2025; ^59 and Public Health England -Public Health England Tuberculosis Strategy Monitoring Indicators 2015-2020 (in development). ^7	Recommended for Canada by: Pan-Canadian Public Health Network – Guidance for Tuberculosis Prevention and Control Programs in Canada; ^15 FNIHB/Health Canada – Health Canada Strategy against Tuberculosis for First Nations on-Reserve and related Monitoring and Performance Framework; ^13 ^, ^14 and Heffernan & Long – Would program performance indicators and a nationally coordinated response accelerate tuberculosis elimination in Canada? ^64
Indicator, Target and Rationale	Notes
4.3 Proportion of close contacts of persons with smear-positive pulmonary disease who began, and completed, TPT for a diagnosis of LTBI Target: ≥90% Rationale: As above, successful treatment is protective against reactivation of TB (for the infection it is treating); success is a function of completion and strategies to facilitate completion are encouraged, especially for shorter regimens where each dose is a greater contributor to the effectiveness of the therapy. ^96–99	As in 4.2
Precedence
Recommended internationally by: CDC – National Tuberculosis Program Objectives and Performance Targets for 2025. ^59	Recommended for Canada by: Pan-Canadian Public Health Network - Guidance for Tuberculosis Prevention and Control Programs in Canada; ^15 FNIHB - Health Canada Strategy against Tuberculosis for First Nations on-Reserve and Monitoring and Performance Framework;^13 ^, ^14 NCCID - Toward TB Elimination: Shared Priorities for TB Program Performance Measurement in Canada, a Proposal for Discussion; ^17 and Heffernan & Long - Would program performance indicators and a nationally coordinated response accelerate tuberculosis elimination in Canada? ^64

Abbreviations: TB, tuberculosis; NCCID, National Collaborating Center for Infectious Diseases; WHO, World Health Organization; CDC, Centers for Disease Control and Prevention; FNIHB, First Nations and Inuit Health Branch; ROI, return on investment; HIV, human immunodeficiency virus; P/T, provincial and territorial; NAAT, nucleic acid amplification test; CI, confidence interval; aOR, adjusted odds ratio; TST, tuberculin skin test; AFB, acid fast bacillus; CXR, chest radiograph; ITK, Inuit Tapiriit Kanatami; 4R, daily rifampin for 4 months; 9INH, 9-month daily isoniazid regimen; TPT, tuberculosis preventive treatment; LTBI, latent tuberculosis infection

Table 2. Calculating and presenting TB program performance indicators.

Goal of Elimination
	How to calculate performance for reporting
1.0	Numerator: Number of TB cases who are notified in the jurisdiction between January 1 and December 31, inclusive. Denominator: Total mid-year population estimate. Formula: $\frac{\mathrm{\#}\text{of annual incident TB cases}}{\text{Mid}-\text{year population estimate}}*100,00$ In addition, calculate the necessary annual rate of decline to achieve pre-elimination within the jurisdiction (see below) where “years of difference” is the period between the year of reporting and 2035 and the target of 1 is the numerator. $\text{Annual}\%\text{Change}={\frac{1\mathrm{(}\text{pre}-\text{elimination target},\text{per}100,000\text{population by}2035}{\text{crude rate per}100,000\text{population in year of reporting}}}^{\text{Years of difference}}-1*100$
Objectives for examination of immigrants and refugees
2.0	Numerator: Number of Immigration, Refugees, and Citizenship Canada (IRCC) referrals dating from July 1 of the preceding year whose first appointment by a physician or designated public health specialist was achieved within six months of the date the referral was received. Denominator: Total number of IRCC referrals to the public health authority in the jurisdiction between July 1 and June 30. Formula: $\frac{\mathrm{\#}\text{of clients referred by IRCC for medical surveillance assessed within a period}\mathrm{\pounds }180\text{days}}{\text{Total}\mathrm{\#}\text{of clients referred by IRCC for medical surveillance within the previous}12\text{months}}*100$
Objectives for case management and treatment
3.0	Numerator: Number of TB cases notified between January 1 and December 31 whose human immunodeficiency virus (HIV) status is known at the commencement of treatment. Denominator: Total number of TB cases treated. Formula: $\left\{\frac{\mathrm{\#}\text{of annual incident TB casee with known HIV test results}}{\mathrm{\#}\text{annual incident TB case treated with}\mathrm{>}1\text{anti}-\text{TB durg}}\right\}*100$ HIV results include the following possibilities HIV-positive: medical documentation of a positive HIV test at any point in time. HIV-negative: medical documentation of a negative HIV test no more than 90 days before the start date of treatment for TB.
3.1	Numerator: Number of smear-positive (S), pulmonary TB (PTB) cases notified between January 1 and December 31 who initiate treatment within 72 hours of a positive nucleic acid amplification test (NAAT). Denominator: Total number of smear-positive, pulmonary TB cases. Formula: $\frac{\mathrm{\#}\text{of S}+\text{PTB case who initiate treatment within}72\text{hours of a positive NAAT}}{\text{Total}\mathrm{\#}\text{of S}+\text{PTB cases}}*100$
3.2	Numerator: Number of eligible smear-positive (S), rifampin-susceptible (by nucleic acid amplification test (NAAT)) pulmonary TB (PTB) cases notified between January 1 and December 31 who start four anti-TB drugs. Denominator: Total number of eligible TB cases treated. Exclusions: Patients judged to be at high risk for hepatoxicity, gout, and/or have a history of overt exposure to a source case who is known to have had drug resistant TB (any first-line anti-TB drug), and patients who have been previously treated will not count in the numerator or denominator. Formula: $\frac{\mathrm{\#}\text{of rifampin}-\text{susceptible}\mathrm{(}\text{by NAAT}\mathrm{)}\mathrm{S}+\text{PTB cases who initiate}4\text{anti}-\text{TB drugs}}{\mathrm{\#}\text{of eligible S}+\text{PTB cases}}*100$
3.3	Numerator: Number of all culture positive (C), pulmonary TB (PTB) cases who have sputum submitted for acid fast bacillus (AFB) smear/culture, and a chest radiograph (CXR) within two weeks of the end of the initial phase of treatment. Denominator: Total number of culture-positive pulmonary TB cases who are alive and not transferred out at the end of the initial phase of treatment. Exclusions: Patients who die during the initial phase and/or transfer out of the jurisdiction before the end of the initial phase will not count in the numerator or denominator. Formula: $\frac{\mathrm{\#}\text{of C}+\text{PTB cases with AFB smear}/\text{culture and CXR with}2\text{weeks of the end of the initial phase}}{\mathrm{\#}\text{of eligibel C}+\text{PTB cases who initiated treatment},\text{and are alive at the end of the initial phase}}*100$
3.4	Numerator: Number of annual incident TB cases notified in the preceding 12 months who were cured or completed treatment. Denominator: Total number of annual incident TB cases notified in the preceding 12 months who were alive at diagnosis, and who started ≥ one anti-TB drug. Exclusions: Patients with rifampin resistance, patients whose treatment was initiated in another Canadian jurisdiction (transferred in), and patients who have transferred out of country during treatment are excluded from the numerator and denominator. Formula: $\left\{\frac{\mathrm{\#}\text{of notified cases in the preceding year}\mathrm{(}\text{all forms}\mathrm{)}\text{who were cured or completed treatment}}{\mathrm{\#}\text{of notified cases in the preceding year alive at diagnosis},\text{who started}\mathrm{>}1\text{anti}-\text{TB drug}}\right\}*100$
3.5	Does the TB program have dedicated social worker support? If yes, their performance should be monitored according to the objective needs of patients and clients in the jurisdiction (See section 5.3 for examples). If no, the program, under the direction of the program manager/lead, should define the objective needs of underserved patients and clients in the program to advocate for dedicate social worker support.
Objectives for contact management
4.0	Numerator: Number of close (household and non-household) contacts of smear-positive (S) pulmonary TB (PTB) cases notified between January 1 and December 31 whose initial contact encounter was within 3 working days of the contact having been listed. Denominator: Total number of close contacts of annual incident smear-positive pulmonary TB cases. Formula: $\frac{\mathrm{\#}\text{of close contracts of S}+\text{PTB source case whose initial contact encounter occurs within}3\text{days}}{\mathrm{\#}\text{of close contacts of S}+\text{PTB source cases}}*100$
4.1	Numerator: Number of close (household and non-household) contacts of smear-positive (S) pulmonary TB (PTB) cases notified between January 1 and December 31 who are completely assessed*. Denominator: Total number of close contacts of annual incident smear-positive, pulmonary TB cases. Formula: $\frac{\mathrm{\#}\text{of completely assessed close contacts of S}+\text{PTB source cases}}{\mathrm{\#}\text{of close contacts of S}+\text{PTB source cases}}*100$ * A complete assessment consists of: Testing for LTBI as indicated, a medical evaluation and CXR if indicated, plus sputum exams if needed (For more details, see Chapter 4).
4.2	Numerator: Number of close (household and non-household) contacts of smear-positive pulmonary TB cases notified between January 1 and December 31 eligible for TB preventive therapy (TPT) who initiate treatment, Denominator: Total number of close contacts of annual incident smear-positive pulmonary TB cases, who are eligible for TPT. Formula: $\left\{\frac{\mathrm{\#}\text{of close contacts of S}+\text{PTB source case eligible for TPT who initiate}}{\mathrm{\#}\text{of close contacts of S}+\text{PTB source eligibel for TPT}}\right\}*100$
4.3	Numerator: Number of close (household and non-household) contacts of smear-positive (S) pulmonary TB (PTB) cases notified between January 1 and December 31 eligible for TB preventive therapy (TPT) who initiated and complete treatment Denominator: Total number of close contacts of annual incident smear-positive pulmonary TB cases, eligible for TPT who initiated treatment of latent TB infection. Formula: $\frac{\mathrm{\#}\text{of close contacts of S}+\text{PTB source cases who completed TPT}}{\mathrm{\#}\text{of close contacts of S}+\text{PTB source cases who initiated TPT}}*100$

Government of Canada, Public Health Agency of Canada. Reported cases from 1924 to 2019 in Canada - Notifiable diseases on-line. https://diseases.canada.ca/notifiable/charts?c=pl. Published 2000. Updated Accessed January 1, 2000.

 Google Scholar

Proceedings of the National Consensus Conference on Tuberculosis. December 3-5, 1997. 1998;24(Supplement 2):1-24.

 Google Scholar

The global plan to stop TB 2006-2015: actions for life: towards a world free of tuberculosis. Geneva: Stop TB Partnership; 2006.

 Google Scholar

World Health Organization. The End TB Strategy. https://www.who.int/tb/strategy/End_TB_Strategy.pdf. Published 2015. Accessed July 5, 2021.

 Google Scholar

World Health Organization. Compendium of Indicators for Monitoring and Evaluating National Tuberculosis Programs. Geneva: World Health Organization; 2004.

 Google Scholar

Henderson DA. The challenge of eradication: lessons from past eradication campaigns. Int J Tuberc Lung Dis. 1998;2(9 Suppl 1): S4–S8.

 Web of Science ®Google Scholar

World Health Organization. International Health Regulations. Geneva: WHO Press; 2005.

 Google Scholar

Pan-Canadian Public Health Network. Guidance for Tuberculosis Prevention and Control Programs in Canada. 2013.

 Google Scholar

Bareja C, Waring J, Stapledon R, Toms C, Douglas P. Tuberculosis notifications in Australia. Commun Dis Intell. 2011;38(4):E356–E368. 2014;

 Google Scholar

Minnesota Department of Health. Published 2021. https://www.health.state.mn.us/diseases/tb/stats/index.html. Accessed Jul 6, 2021.

 Google Scholar

California Department of Public Health. TB Performance Trends for National and California Objectives. 2016.

 Google Scholar

Health Canada. Health Canada’s Monitoring and Performance Framework for Tuberculosis Programs for First Nations on-Reserve. Feb 12 2016.

 Google Scholar

Haworth-Brockman M, Balakumar S, Head B, Keynan Y. Towards TB Elimination: Shared Priorities for TB Program Performance Measurement in Canada, a Proposal for Discussion. Winnipeg, Manitoba: National Collaborating Centre for Infectious Diseases; June 2019. 453.

 Google Scholar

Langlois-Klassen D, Wooldrage KM, Manfreda J, et al. Piecing the puzzle together: foreign-born tuberculosis in an immigrant-receiving country. European Respiratory Journal. 2011;38(4):895–902. doi:10.1183/09031936.00196610.

 PubMed Web of Science ®Google Scholar

Stop TB Partnership, World Health Organization. The Global Plan to Stob TB 2011-2015: transforming the Fight towards Elimination of Tuberculosis. Geneva: World Health Organization; 2011.

 Google Scholar

Chan IHY, Kaushik N, Dobler CC. Post-migration follow-up of migrants identified to be at increased risk of developing tuberculosis at pre-migration screening: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2017;17(7):770–779. doi:10.1016/S1473-3099(17)30194-9.

 PubMed Web of Science ®Google Scholar

Asadi L, Heffernan C, Menzies D, Long R. Effectiveness of Canada’s tuberculosis surveillance strategy in identifying immigrants at risk of developing and transmitting tuberculosis: a population-based retrospective cohort study. The Lancet Public Health. 2017;2(10):e450–e457. doi:10.1016/S2468-2667(17)30161-5.

 PubMed Web of Science ®Google Scholar

Long R, Asadi L, Heffernan C, et al. Is there a fundamental flaw in Canada’s post-arrival immigrant surveillance system for tuberculosis? PLOS One. 2019;14(3):e0212706. doi:10.1371/journal.pone.0212706.

 PubMed Web of Science ®Google Scholar

Ronald LA, Campbell JR, Rose C, et al. Estimated impact of World Health Organization latent tuberculosis screening guidelines in a region with a low tuberculosis incidence: retrospective cohort study. Clin Infect Dis. 2019;69(12):2101–2108. doi:10.1093/cid/ciz188.

 PubMed Web of Science ®Google Scholar

Alaska Departement of Health and Social Services. Alaska Tuberculosis Program Manual. 2017.

 Google Scholar

Heffernan C, Long R. Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada? Can J Public Health. 2019;110(1):31–35. doi:10.17269/s41997-018-0106-x.

 PubMed Web of Science ®Google Scholar

Long R, Ellis E. Public Health Agency of Canada, Canadian Lung Association, Canadian Thoracic Society. Canadian Tuberculosis Standards. 2007.

 Google Scholar

Rutstein SE, Ananworanich J, Fidler S, et al. Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. J Int AIDS Soc. 2017;20(1):21579. doi:10.7448/IAS.20.1.21579.

 PubMed Web of Science ®Google Scholar

Long R, Niruban S, Heffernan C, et al. A 10-year population based study of ‘opt-out’ HIV testing of tuberculosis patients in Alberta, Canada: national implications. PLoS One. 2014;9(6):e98993. doi:10.1371/journal.pone.0098993.

 PubMed Web of Science ®Google Scholar

Bogers SJ, Hulstein SH, Schim van der Loeff MF, et al. Current evidence on the adoption of indicator condition guided testing for HIV in western countries: A systematic review and meta-analysis. EClinicalMedicine. 2021;35:100877. doi:10.1016/j.eclinm.2021.100877.

 PubMedGoogle Scholar

World Health Organization, UNAIDS, The Global Fund, PEPFAR. A Guide to Monitoring and Evaluation for Collaborative TB/HIV Activities-2015 Revisions. Geneva: WHO Press; 2015.

 Google Scholar

Canadian Medical Association. Guidelines for the identification, investigation and treatment of individuals with concomitant tuberculosis and HIV infection. Bureau of Communicable Disease Epidemiology, Canada Department of National Health and Welfare. CMAJ. 1993;148(11):1963–1970.

 Web of Science ®Google Scholar

Long R, Houston S, Hershfield E. Canadian Tuberculosis Committee of the Centre for Infectious Disease P, Control P, Public Health Branch HC. Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts. CMAJ. 2003;169(8):789–791.

 PubMed Web of Science ®Google Scholar

Haworth-Brockman MJ, Keynan Y. Strengthening tuberculosis surveillance in Canada. CMAJ. 2019;191(26):E743–E744. doi:10.1503/cmaj.72225.

 PubMed Web of Science ®Google Scholar

Migliori GB, Nardell E, Yedilbayev A, et al. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe. Eur Respir J. 2019;53(6):1900391. doi:10.1183/13993003.00391-2019.

 PubMed Web of Science ®Google Scholar

Golub JE, Bur S, Cronin WA, et al. Delayed tuberculosis diagnosis and tuberculosis transmission. The International Journal of Tuberculosis and Lung Disease. 2006;10(1):24–30.

 PubMed Web of Science ®Google Scholar

Mitchison DA. Infectivity of patients with pulmonary tuberculosis during chemotherapy. Eur Respir J. 1990;3(4):385–386.

 Web of Science ®Google Scholar

LaFreniere M, Dam D, Strudwick L, McDermott S. Tuberculosis drug resistance in Canada: 2018. Can Commun Dis Rep. 2020;46(1):9–15. doi:10.14745/ccdr.v46i01a02.

 PubMedGoogle Scholar

Public Health England. Collaborative TB Strategy for England, 2015 to 2020: end of programme report. 2015. GW-1954.

 Google Scholar

Health Canada. Health Canada’s Strategy against Tuberculosis for First Nations on-Reserve. Ottawa, Ont.: Health Canada; 2012.

 Google Scholar

Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet (London, England). 2002;360(9332):528–534.

 PubMed Web of Science ®Google Scholar

Calderwood CJ, Wilson JP, Fielding KL, et al. Dynamics of sputum conversion during effective tuberculosis treatment: A systematic review and meta-analysis. PLOS Med. 2021;18(4):e1003566. doi:10.1371/journal.pmed.1003566.

 PubMed Web of Science ®Google Scholar

Center for Disease Control. TB - National TB Program Objectives and Performance Targets for 2025. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/tb/programs/evaluation/indicators/default.htm. Published 2019. Accessed September 18, 2019.

 Google Scholar

World Health Organization. WHA44.8 TUBERCULOSIS CONTROL PROGRAMME. 1991.

 Google Scholar

Australian Government Department of Health and Ageing. The strategic plan for control of tuberculosis in Australia: 2011–2015. Australian Government Department of Health and Ageing. www1.health.gov.au. Accessed June 30, 2021.

 Google Scholar

Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, Porter JDH. The Social Determinants of Tuberculosis: From Evidence to Action. Am. J. Public Health. 2011;101(4):654–662. doi:10.2105/AJPH.2010.199505.

 PubMed Web of Science ®Google Scholar

Veen J. Microepidemics of tuberculosis: the stone-in-the-pond principle. Tuber Lung Dis. 1992;73(2):73–76. doi:10.1016/0962-8479(92)90058-R.

 PubMedGoogle Scholar

Fox GJ, Dobler CC, Marks GB. Active case finding in contacts of people with tuberculosis. The Cochrane Database of Systematic Reviews. 2011;(9):CD008477. doi:10.1002/14651858.CD008477.pub2.

 PubMed Web of Science ®Google Scholar

National Tuberculosis Controllers A, Centers for Disease C, Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54(RR-15):1–47.

 Google Scholar

Luzzati R, Migliori GB, Zignol M, et al. Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. Eur Respir J. 2017;50(5):1701414. doi:10.1183/13993003.01414-2017.

 PubMed Web of Science ®Google Scholar

Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. The New England Journal of Medicine. 1992;326(4):231–235. doi:10.1056/NEJM199201233260404.

 PubMed Web of Science ®Google Scholar

Canada PHAo. Chapter 12: Canadian Tuberculosis Standards 7th Edition: 2014 – Contact follow-up and outbreak management in Tuberculosis control. Published 2014. https://www.canada.ca/en/public-health/services/infectious-diseases/canadian-tuberculosis-standards-7th-edition/edition-8.html. Accessed February 17, 2014.

 Google Scholar

Cormier M, Schwartzman K, N’Diaye DS, et al. Proximate determinants of tuberculosis in Indigenous peoples worldwide: a systematic review. The Lancet Global Health. 2019;7(1):e68–e80. doi:10.1016/S2214-109X(18)30435-2.

 PubMed Web of Science ®Google Scholar

Ai J-W, Ruan Q-L, Liu Q-H, Zhang W-H. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerging Microbes Infect. 2016;5(2):e10. doi:10.1038/emi.2016.10.

 PubMedGoogle Scholar

Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–453. doi:10.1056/NEJMoa1714283.

 PubMed Web of Science ®Google Scholar

Macaraig MM, Jalees M, Lam C, Burzynski J. Improved treatment completion with shorter treatment regimens for latent tuberculous infection. Int j Tuberc Lung Dis. 2018;22(11):1344–1349. doi:10.5588/ijtld.18.0035.

 PubMed Web of Science ®Google Scholar